MegaNano Biotech Files Vaccine Patent Using Dendritic Cells
Summary
The USPTO published patent application US20260097104A1 filed by MegaNano Biotech, Inc. on June 12, 2025, covering antigen sensitized exogenous immature dendritic cells for vaccine formulations. The application discloses methods of using dead antigen sensitized exogenous immature dendritic cells to elicit immune responses and methods of disease treatment and prevention.
What changed
The USPTO published patent application US20260097104A1 for MegaNano Biotech, Inc., covering dendritic cell-based vaccine compositions and methods. The application discloses antigen sensitized exogenous immature dendritic cells, including dead dendritic cells, for eliciting immune responses and treating or preventing diseases. The filing date was June 12, 2025, with the application published on April 9, 2026.
Affected parties including pharmaceutical companies, biotechnology firms, and vaccine developers should monitor this application as it may indicate competitive activity in the dendritic cell vaccine space. The patent claims, if granted, could affect freedom-to-operate considerations for parties developing similar immunotherapies.
What to do next
- Monitor for updates on patent prosecution status
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods of Formulating a Vaccine
Application US20260097104A1 Kind: A1 Apr 09, 2026
Assignee
MegaNano Biotech, Inc.
Inventors
Chuanhai Cao
Abstract
Disclosed herein are antigen sensitized exogenous immature dendritic cells. The dendritic cell may also be dead. Antigen sensitized dead exogenous immature dendritic cells may be used to elicit an immune response or reactivate the immune system. Further provided are vaccines comprising the dead antigen sensitized exogenous immature dendritic cells, methods of formulating vaccines, methods of inducing an immune response in a patient, and methods of treating a disease and methods of disease prevention.
CPC Classifications
A61K 39/0007 A61K 40/19 A61K 40/22 A61K 40/24 A61K 40/416 A61K 40/42 A61P 25/28 C12N 5/064 A61K 35/15 A61K 2039/545 A61K 2039/572 A61K 2039/575
Filing Date
2025-06-12
Application No.
19235990
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.